Oculis Holding’s OCS-05 phase 2 ACUITY trial in acute optic neuritis meets primary safety endpoint and key secondary efficacy endpoints: Zug, Switzerland Tuesday, January 7, 202 ...
The majority of us don’t need to consume this supplement, experts say, but it can be useful in certain situations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback